Bloomage Biotechnology Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 4,444

Employees

  • Stock Symbol
  • 688363

Stock Symbol

  • Investments
  • 9

  • Share Price
  • $7.08
  • (As of Wednesday Closing)

Bloomage Biotechnology General Information

Description

Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid sodium, or HA. The firm organizes itself into two segments based on product type. The HA raw materials segment, which generates the majority of revenue, sells HA and HA derivatives produced using bio-fermentation technology. The HA raw materials segment products are classified into three grades of HA: medicine grade, cosmetic grade, and food grade. The HA end products segment sells medical skin care products, bone products for intra-articular injection, and medical beauty devices. The majority of revenue comes from China.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Tower D, Bloomage International Center
  • Floor 33, 6A, Jianguomenwai Avenue
  • Beijing
  • China
+86 010
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
SHG
Corporate Office
  • Tower D, Bloomage International Center
  • Floor 33, 6A, Jianguomenwai Avenue
  • Beijing
  • China
+86 010

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bloomage Biotechnology Stock Performance

As of 18-Jun-2025, Bloomage Biotechnology’s stock price is $7.08. Its current market cap is $3.41B with 482M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.08 $7.27 $5.84 - $12.05 $3.41B 482M 3.52M

Bloomage Biotechnology Financials Summary

As of 31-Mar-2025, Bloomage Biotechnology has a trailing 12-month revenue of $706M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 3,177,609 3,338,496 4,404,626 9,135,077
Revenue 706,184 748,491 858,802 944,265
EBITDA 6,410 70,861 132,674 196,853
Net Income 4,551 24,287 83,755 144,170
Total Assets 1,175,327 1,185,837 1,194,877 1,258,353
Total Debt 56,505 49,272 29,357 56,497
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bloomage Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bloomage Biotechnology‘s full profile, request access.

Request a free trial

Bloomage Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bloomage Biotechnology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bloomage Biotechnology‘s full profile, request access.

Request a free trial

Bloomage Biotechnology Investments & Acquisitions (9)

Bloomage Biotechnology’s most recent deal was a Later Stage VC with SHINEHIGH INNOVATION for . The deal was made on 01-Apr-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
SHINEHIGH INNOVATION 01-Apr-2025 Later Stage VC Biotechnology
Hefei HRG Longyan Intelligent Equipment 26-Oct-2022 Later Stage VC Paper Containers and Packaging
Yek (Beijing) 19-Jul-2022 Merger/Acquisition Personal Products
Peptites Biotech 29-Jun-2022 Later Stage VC Biotechnology
Revitacare 08-Jan-2017 Merger/Acquisition Other Devices and Supplies
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

Bloomage Biotechnology ESG

Risk Overview

Risk Rating

Updated May, 20, 2025

31.36 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Household Products

Industry

of 104

Rank

Percentile

Personal Products

Subindustry

of 81

Rank

Percentile

To view Bloomage Biotechnology’s complete esg history, request access »

Bloomage Biotechnology Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Revitacare Paris, France 2003
Yek (Beijing) Beijing, China 1997

Bloomage Biotechnology FAQs

  • When was Bloomage Biotechnology founded?

    Bloomage Biotechnology was founded in 2006.

  • Where is Bloomage Biotechnology headquartered?

    Bloomage Biotechnology is headquartered in Beijing, China.

  • What is the size of Bloomage Biotechnology?

    Bloomage Biotechnology has 4,444 total employees.

  • What industry is Bloomage Biotechnology in?

    Bloomage Biotechnology’s primary industry is Biotechnology.

  • Is Bloomage Biotechnology a private or public company?

    Bloomage Biotechnology is a Public company.

  • What is Bloomage Biotechnology’s stock symbol?

    The ticker symbol for Bloomage Biotechnology is 688363.

  • What is the current stock price of Bloomage Biotechnology?

    As of 18-Jun-2025 the stock price of Bloomage Biotechnology is $7.08.

  • What is the current market cap of Bloomage Biotechnology?

    The current market capitalization of Bloomage Biotechnology is $3.41B.

  • What is Bloomage Biotechnology’s current revenue?

    The trailing twelve month revenue for Bloomage Biotechnology is $706M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »